CLSA: Lowers Alibaba Health (00241.HK) target price to HK$3.7, maintains "Outperform" rating

Zhito Finance APP has learned that CLSA issued a research report stating that, as subsidy cuts and regulatory headwinds weighed on nutritional product sales, Alibaba Health (00241.HK) lowered its revenue outlook for fiscal year 2027. The bank cut its target price for Alibaba Health from HK$4.7 to HK$3.7, maintaining an "Outperform" rating.